CoChat
Sign Up
Cited by 199

The DOI matches its Crossref record.

Protective roles of SIRT1 in atherosclerosis

Stein, Sokrates, Matter, Christian M.·2011·Cell Cycle
DOI 10.4161/cc.10.4.14863
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/cc.10.4.14863

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 90

  1. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998; 20:615-26.
  2. Michan S, Sinclair D. Sirtuins in mammals: Insights into their biological function. Biochem J 2007; 404:1-13.
  3. Denu JM. The Sir 2 family of protein deacetylases. Curr Opin Chem Biol 2005; 9:431-40.
  4. Tanner KG, Landry J, Sternglanz R, Denu JM. Silent information regulator 2 family of NAD-dependent histone/protein deacetylases generates a unique prod- uct, 1-O-acetyl-ADP-ribose. Proc Natl Acad Sci USA 2000; 97:14178-82.
  5. Avalos JL, Bever KM, Wolberger C. Mechanism of sir- tuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell 2005; 17:855-68.
  6. Rine J, Herskowitz I. Four genes responsible for a position effect on expression from HML and HMR in Saccharomyces cerevisiae. Genetics 1987; 116:9-22.
  7. Maillet L, Boscheron C, Gotta M, Marcand S, Gilson E, Gasser SM. Evidence for silencing compartments within the yeast nucleus: A role for telomere proxim- ity and Sir protein concentration in silencer-mediated repression. Genes Dev 1996; 10:1796-811.
  8. Gottlieb S, Esposito RE. A new role for a yeast tran- scriptional silencer gene, SIR2, in regulation of recom- bination in ribosomal DNA. Cell 1989; 56:771-6.
  9. Tsang AW, Escalante-Semerena JC. CobB, a new member of the SIR2 family of eucaryotic regulatory proteins, is required to compensate for the lack of nico- tinate mononucleotide: 5,6-dimethylbenzimidazole phosphoribosyltransferase activity in cobT mutants during cobalamin biosynthesis in Salmonella typhimuri- um LT2. J Biol Chem 1998; 273:31788-94.
  10. Brachmann CB, Sherman JM, Devine SE, Cameron EE, Pillus L, Boeke JD. The SIR2 gene family, con- served from bacteria to humans, functions in silencing, cell cycle progression and chromosome stability. Genes Dev 1995; 9:2888-902.
  11. Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 1999; 260:273-9.
  12. Gracia-Sancho J, Villarreal G Jr, Zhang Y, Garcia- Cardena G. Activation of SIRT1 by resveratrol induces KLF2 expression conferring an endothelial vasoprotec- tive phenotype. Cardiovasc Res 2010; 85:514-9.
  13. Csiszar A, Labinskyy N, Podlutsky A, Kaminski PM, Wolin MS, Zhang C, et al. Vasoprotective effects of resveratrol and SIRT1: Attenuation of cigarette smoke- induced oxidative stress and proinflammatory phe- notypic alterations. Am J Physiol Heart Circ Physiol 2008; 294:2721-35.
  14. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NFkappaB signaling. J Biol Chem 2005; 280:40364-74.
  15. Clarke M, Bennett M. Defining the role of vascular smooth muscle cell apoptosis in atherosclerosis. Cell Cycle 2006; 5:2329-31.
  16. Weissberg PL, Clesham GJ, Bennett MR. Is vascular smooth muscle cell proliferation beneficial? Lancet 1996; 347:305-7.
  17. Ho C, van der Veer E, Akawi O, Pickering JG. SIRT1 markedly extends replicative lifespan if the NAD + salvage pathway is enhanced. FEBS Lett 2009; 583:3081-5.
  18. Cardellini M, Menghini R, Martelli E, Casagrande V, Marino A, Rizza S, et al. TIMP3 is reduced in athero- sclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 2009; 58:2396-401.
  19. Zhang HN, Li L, Gao P, Chen HZ, Zhang R, Wei YS, et al. Involvement of the p65/RelA subunit of NFkappaB in TNFalpha-induced SIRT1 expression in vascular smooth muscle cells. Biochem Biophys Res Commun 2010; 397:569-75.
  20. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degrada- tion of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979; 76:333-7.
  21. Steinberg D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nat Med 2002; 8:1211-7.
  22. Stein S, Lohmann C, Schäfer N, Hofmann J, Rohrer L, Besler C, et al. SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J 2010; PMID: 20418343; DOI: 10.1093/eurheartj/ehq107. · DOI · Paper page
  23. Yang Z, Kahn BB, Shi H, Xue BZ. Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antago- nizes fatty acid-induced inflammation through SIRT1. J Biol Chem 2010; 285:19051-9.
  24. Shen Z, Ajmo JM, Rogers CQ, Liang X, Le L, Murr MM, et al. Role of SIRT1 in regulation of LPS-or two ethanol metabolites-induced TNFalpha produc- tion in cultured macrophage cell lines. Am J Physiol Gastrointest Liver Physiol 2009; 296:1047-53.
  25. Yoshizaki T, Schenk S, Imamura T, Babendure JL, Sonoda N, Bae EJ, et al. SIRT1 inhibits inflamma- tory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab 2010; 298:419-28.
  26. Zhang R, Chen HZ, Liu JJ, Jia YY, Zhang ZQ, Yang RF, et al. SIRT1 suppresses activator protein-1 tran- scriptional activity and cyclooxygenase-2 expression in macrophages. J Biol Chem 2010; 285:7097-110.
  27. Nakamaru Y, Vuppusetty C, Wada H, Milne JC, Ito M, Rossios C, et al. A protein deacetylase SIRT1 is a nega- tive regulator of metalloproteinase-9. FASEB J 2009; 9:2810-9; PMID: 19376817.
  28. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002; 8:1235-42.
  29. Bitterman KJ, Anderson RM, Cohen HY, Latorre- Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 2002; 277:45099-107.
  30. Thurberg BL, Collins T. The nuclear factor kappaB/ inhibitor of kappaB autoregulatory system and athero- sclerosis. Curr Opin Lipidol 1998; 9:387-96.
  31. Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 2000; 105:451-8.
  32. Chien S. Effects of disturbed flow on endothelial cells. Ann Biomed Eng 2008; 36:554-62.
  33. Chen Z, Peng IC, Cui X, Li YS, Chien S, Shyy JY. Shear stress, SIRT1 and vascular homeostasis. Proc Natl Acad Sci USA 2010; 107:10268-73.
  34. Kawashima S, Yokoyama M. Dysfunction of endotheli- al nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24:998-1005.
  35. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 2010; 459:923-39.
  36. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, et al. Endothelial regulation of vaso- motion in apoE-deficient mice: Implications for inter- actions between peroxynitrite and tetrahydrobiopterin. Circulation 2001; 103:1282-8.
  37. Mueller CF, Laude K, McNally JS, Harrison DG. ATVB in focus: Redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol 2005; 25:274-8.
  38. Stokes KY, Clanton EC, Russell JM, Ross CR, Granger DN. NAD(P)H oxidase-derived superoxide mediates hypercholesterolemia-induced leukocyte-endothelial cell adhesion. Circ Res 2001; 88:499-505.
  39. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: Testing and clinical rel- evance. Circulation 2007; 115:1285-95.
  40. Miyazaki R, Ichiki T, Hashimoto T, Inanaga K, Imayama I, Sadoshima J, et al. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28:1263-9.
  41. Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G, et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 2008; 80:191-9.
  42. Stein S, Schafer N, Breitenstein A, Besler C, Winnik S, Lohmann C, et al. SIRT1 reduces endothelial activation without affecting vascular function in ApoE -/-mice. Aging (Albany NY) 2010; 2:353-60.
  43. Pirola L, Frojdo S. Resveratrol: one molecule, many targets. IUBMB Life 2008; 60:323-32.
  44. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009; 74:619-24.
  45. Milne JC, Denu JM. The Sirtuin family: Therapeutic targets to treat diseases of aging. Curr Opin Chem Biol 2008; 12:11-7.
  46. Yang Z, Ming XF. The vascular SIRTainty. Aging (Albany NY) 2010; 2:331-2.
  47. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothe- lial cell adhesion molecules: NFkappaB and cytokine- inducible enhancers. FASEB J 1995; 9:899-909.
  48. Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ, Kardakaris R, et al. Endothelial cell-specific NFkappaB inhibition protects mice from atherosclero- sis. Cell Metab 2008; 8:372-83.
  49. Wood KM, Cadogan MD, Ramshaw AL, Parums DV. The distribution of adhesion molecules in human ath- erosclerosis. Histopathology 1993; 22:437-44.
  50. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: An update. Arterioscler Thromb Vasc Biol 2008; 28:1897-908.
  51. Csiszar A, Labinskyy N, Jimenez R, Pinto JT, Ballabh P, Losonczy G, et al. Anti-oxidative and anti-inflammato- ry vasoprotective effects of caloric restriction in aging: Role of circulating factors and SIRT1. Mech Ageing Dev 2009; 130:518-27.
  52. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004; 73:417-35.
  53. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999; 13:2570-80.
  54. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403:795-800.
  55. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 2000; 289:2126-8.
  56. Lin SJ, Ford E, Haigis M, Liszt G, Guarente L. Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev 2004; 18:12-6.
  57. Lin SJ, Kaeberlein M, Andalis AA, Sturtz LA, Defossez PA, Culotta VC, et al. Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respira- tion. Nature 2002; 418:344-8.
  58. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001; 410:227-30.
  59. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, et al. Sirtuin activators mimic caloric restric- tion and delay ageing in metazoans. Nature 2004; 430:686-9.
  60. Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci USA 2004; 101:15998-6003.
  61. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009; 325:201-4.
  62. Kaeberlein M. Lessons on longevity from budding yeast. Nature 2010; 464:513-9.
  63. Kaeberlein M, Powers RW, 3rd. Sir2 and calorie restric- tion in yeast: A skeptical perspective. Ageing Res Rev 2007; 6:128-40.
  64. Baur JA, Chen D, Chini EN, Chua K, Cohen HY, de Cabo R, et al. Dietary restriction: Standing up for sirtuins. Science 2010; 329:1012-3.
  65. Fontana L, Partridge L, Longo VD. Extending healthy life span-from yeast to humans. Science 2010; 328:321-6.
  66. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, et al. Sirt1 pro- motes fat mobilization in white adipocytes by repress- ing PPAR-gamma. Nature 2004; 429:771-6.
  67. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, et al. SIRT1 promotes endo- thelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2007; 104:14855-60.
  68. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127:1109-22.
  69. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeo- stasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434:113-8.
  70. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NFkappaB- dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23:2369-80.
  71. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007; 28:91-106.
  72. Tontonoz P, Spiegelman BM. Fat and Beyond: The Diverse Biology of PPARgamma. Annu Rev Biochem 2008; 77:289-312.
  73. Kim HJ, Park KG, Yoo EK, Kim YH, Kim YN, Kim HS, et al. Effects of PGC-1alpha on TNFalpha-induced MCP-1 and VCAM-1 expression and NFkappaB acti- vation in human aortic smooth muscle and endothelial cells. Antioxid Redox Signal 2007; 9:301-7.
  74. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450:712-6.
  75. Funk JA, Odejinmi S, Schnellmann RG. SRT1720 induces mitochondrial biogenesis and rescues mito- chondrial function after oxidant injury in renal proximal tubule cells. J Pharmacol Exp Ther 2010; 333:593-601.
  76. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, et al. SRT1720, SRT2183, SRT1460 and resveratrol are not direct activators of SIRT1. J Biol Chem 2010; 285:8340-51.
  77. Breitenstein A, Stein S, Holy EW, Camici GG, Lohmann C, Akhmedov A, et al. Sirt1 inhibition induces in vivo arterial thrombosis and tissue fac- tor expression in activated human endothelial cells. Cardiovasc Res 2010; 89:464-72; PMID: 20978007.
  78. Reilly MP, Rohatgi A, McMahon K, Wolfe ML, Pinto SC, Rhodes T, et al. Plasma cytokines, metabolic syn- drome and atherosclerosis in humans. J Investig Med 2007; 55:26-35.
  79. Annex BH, Denning SM, Channon KM, Sketch MH Jr, Stack RS, Morrissey JH, et al. Differential expression of tissue factor protein in directional atherectomy speci- mens from patients with stable and unstable coronary syndromes. Circulation 1995; 91:619-22.
  80. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349:769-71.
  81. Sequeira J, Boily G, Bazinet S, Saliba S, He X, Jardine K, et al. sirt1-null mice develop an autoimmune-like condition. Exp Cell Res 2008; 314:3069-74.
  82. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:861-70.
  83. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA 2001; 98:15113-8.
  84. Hirao M, Posakony J, Nelson M, Hruby H, Jung M, Simon JA, et al. Identification of selective inhibitors of NAD + -dependent deacetylases using phenotypic screens in yeast. J Biol Chem 2003; 278:52773-82.
  85. Posakony J, Hirao M, Stevens S, Simon JA, Bedalov A. Inhibitors of Sir2: Evaluation of splitomicin analogues. J Med Chem 2004; 47:2635-44.
  86. Prozorovski T, Schulze-Topphoff U, Glumm R, Baumgart J, Schroter F, Ninnemann O, et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol 2008; 10:385-94.
  87. Kim EJ, Kho JH, Kang MR, Um SJ. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppres- sion of p53 activity. Mol Cell 2007; 28:277-90.
  88. Biacsi R, Kumari D, Usdin K. SIRT1 inhibition allevi- ates gene silencing in Fragile X mental retardation syndrome. PLoS Genet 2008; 4:1000017.
  89. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, et al. SIRT1 regulates hepatocyte lipid metabo- lism through activating AMP-activated protein kinase. J Biol Chem 2008; 283:20015-26.
  90. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451:914-8.

Cited by

Sorted by citations

Metadata

Authors
Stein, S., & Matter, C. M.
Venue
Cell Cycle
Publisher
Informa UK Limited
Published
2011-02-15
Volume
10
Issue
4
Pages
640-647
ISSN
  • 1538-4101
  • 1551-4005
DOI
10.4161/cc.10.4.14863
Cited by
199
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review